Last updated: August 3, 2026
Pfizer’s Delaware action against Mylan Laboratories concerned an ANDA seeking approval to market generic pregabalin, the active ingredient in Lyrica. Pfizer asserted patent protection covering pregabalin and methods of treating pain. The case was part of the broader Lyrica generic-entry litigation involving Pfizer and multiple ANDA applicants. The public docket reflects resolution by settlement and dismissal rather than a reported merits judgment determining patent validity or infringement.
What drug and patents were involved in Pfizer v. Mylan?
The dispute involved Lyrica, Pfizer’s brand-name pregabalin product. Lyrica was approved in the United States for several indications, including neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, partial-onset seizures, fibromyalgia, and pain associated with spinal cord injury.[1]
Asserted patent estate
The principal Lyrica patents associated with Pfizer’s ANDA litigation included:
| Patent |
General subject matter |
Patent type |
Approximate nominal expiration |
| U.S. Patent No. 6,001,876 |
Pregabalin compound and pharmaceutical compositions |
Active-ingredient patent |
December 2018 |
| U.S. Patent No. 6,197,819 |
Methods of treating pain with pregabalin |
Method-of-use patent |
December 2018 |
| U.S. Patent No. 6,329,429 |
Additional therapeutic uses of pregabalin |
Method-of-use patent |
December 2018 |
| U.S. Patent No. 6,770,660 |
Certain pregabalin therapeutic uses, including fibromyalgia-related claims |
Method-of-use patent |
Later expiration than the compound patent |
The pleadings and litigation record for the Mylan case should be distinguished from the complete Lyrica Orange Book estate. An ANDA case typically asserts only the patents implicated by the applicant’s Paragraph IV certification or by the relevant product labeling.
What was the legal basis of Pfizer’s lawsuit?
Pfizer brought the action under the Hatch-Waxman Act after receiving notice that Mylan had filed an ANDA containing a Paragraph IV certification.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing the certification and providing notice to the patent holder creates the statutory basis for an infringement action under 35 U.S.C. § 271(e)(2).
The complaint alleged that Mylan’s proposed generic pregabalin product would infringe Pfizer’s Lyrica patents before expiration. Pfizer sought the standard Hatch-Waxman remedies:
- A declaration that the asserted patents were valid and enforceable.
- A declaration that Mylan’s ANDA product would infringe.
- An order requiring FDA approval to be delayed until patent expiration.
- Costs and other relief authorized by the patent laws.
The case did not concern an already marketed generic product. The alleged infringement was based on Mylan’s submission of the ANDA.
What did Mylan challenge in the Lyrica patent case?
Mylan’s Paragraph IV position placed patent validity, enforceability, and infringement at issue. In Lyrica litigation, the central technical and legal disputes generally involved two categories of claims.
Compound and composition claims
The compound patent presented the strongest barrier to an identical generic product if enforceable claims remained in force. A claim covering pregabalin itself could block ordinary generic commercialization across indications during the patent term.
For an ANDA applicant, potential defenses included:
- Invalidity based on anticipation.
- Obviousness.
- Lack of written description or enablement.
- Noninfringement based on the proposed product or manufacturing process.
- Patent expiration or lack of enforceable scope.
Method-of-use claims
The method-of-use patents covered treatment of specified conditions with pregabalin. These patents raised a separate issue because an ANDA applicant could seek approval for fewer than all branded indications.
A generic applicant may use a section viii statement to carve out patented indications from its labeling. That approach can reduce infringement exposure but does not eliminate risk where:
- The remaining label encourages the patented use.
- The product is prescribed for the patented indication.
- The patent claims are not limited to a separable indication.
- The proposed label contains language that supports the patented treatment method.
The Federal Circuit’s later Lyrica-related decisions involving induced infringement and skinny labeling show why method-of-use patents remained commercially significant even after compound-patent protection approached expiration.[2]
What was the outcome of Pfizer v. Mylan, 1:15-cv-00960?
The action was resolved without a publicly reported trial judgment deciding the validity or infringement of the asserted Lyrica patents. The docket reflects a settlement-based dismissal.
The settlement terms were not publicly disclosed in the docket materials. As a result, the public record does not establish:
- The precise agreed generic launch date.
- Whether Mylan received a license covering all or only some pregabalin indications.
- Whether the agreement included authorized-generic provisions.
- Whether Pfizer made any payment to Mylan.
- Whether the parties agreed to restrictions on Mylan’s product labeling.
- Whether the agreement addressed future patent litigation involving additional Lyrica indications.
The absence of a merits judgment is material. The case did not produce a binding Delaware ruling invalidating the asserted patents or confirming their full enforceability against all generic applicants.
When did Lyrica lose exclusivity?
Lyrica’s principal U.S. compound patent expired in late 2018, subject to pediatric exclusivity that extended the effective regulatory barrier into 2019.
| Exclusivity component |
Date or period |
| U.S. approval of Lyrica |
2004 |
| Compound-patent expiration |
December 2018 |
| Pediatric exclusivity |
Approximately six additional months |
| Broad generic availability |
2019 |
| First major generic approvals and launches |
2019 |
FDA approved the first generic versions of pregabalin in 2019 after the relevant patent and pediatric-exclusivity barriers ended.[3] Mylan was among the companies positioned to enter the market following resolution of the Lyrica patent disputes.
The precise commercial launch date depended on the applicant’s settlement terms, FDA approval status, manufacturing readiness, and whether the applicant sought all indications or used a carved-out label.
What was the Orange Book status of Lyrica?
The Orange Book listed patents associated with Lyrica and its approved indications. The listings included both product-related patents and method-of-use patents. Orange Book listing did not itself establish that every listed claim would survive litigation. It did, however, determine the patent certifications that an ANDA applicant had to address.[4]
Orange Book and Paragraph IV exposure
For an ANDA applicant, each listed patent could require one of the following:
- Paragraph I certification: no patent information had been submitted.
- Paragraph II certification: the patent had expired.
- Paragraph III certification: the applicant would wait until patent expiration.
- Paragraph IV certification: the patent was invalid, unenforceable, or not infringed.
- Section viii statement: the applicant would omit a patented method of use.
A Paragraph IV notice from Mylan triggered Pfizer’s right to sue within 45 days. The lawsuit imposed a potential 30-month FDA approval stay, subject to statutory exceptions and court action.
How strong was Pfizer’s Lyrica patent estate?
Pfizer’s Lyrica estate was strongest before compound-patent expiration. The compound patent created a broad barrier against an identical pregabalin product. After that patent expired, Pfizer’s protection depended more heavily on method-of-use patents and label strategy.
Strength by patent category
| Patent category |
Commercial strength before 2019 |
Strength after compound expiration |
| Pregabalin compound |
High |
None after expiration |
| Pharmaceutical composition |
High to moderate |
Limited by product equivalence and expiration |
| Pain-treatment methods |
Moderate to high |
Relevant if generic labeling or conduct supported infringement |
| Fibromyalgia method |
Moderate |
Dependent on carve-out and induced-infringement theories |
| Manufacturing claims |
Case-specific |
Potential barrier only if directly implicated by the ANDA process |
The estate’s practical value declined as the compound patent expired. Method-of-use patents could delay or narrow competition, but they generally did not provide the same market-wide control as a valid compound patent.
What patent litigation affected Lyrica generic entry?
Pfizer pursued Hatch-Waxman litigation against several generic applicants, including Mylan. Separate cases and appellate proceedings addressed related Lyrica patents and different ANDA applicants.
The broader litigation raised recurring issues:
- Whether the asserted pregabalin claims were valid.
- Whether a generic label induced infringement.
- Whether a section viii carve-out effectively removed a patented indication.
- Whether physician prescribing behavior could support induced infringement.
- Whether settlements delayed or authorized generic entry.
- Whether the FDA could approve a product with omitted indications.
The Federal Circuit’s Lyrica decisions involving Pfizer and Teva addressed the relationship between a generic label and induced infringement of method-of-use claims.[2] Those decisions affected the risk analysis for all applicants seeking approval of pregabalin products, including applicants resolving cases through settlement.
Did Pfizer and Mylan enter a settlement agreement?
Yes. The case ended through settlement rather than a public trial decision. The material commercial terms were confidential.
The docket’s dismissal therefore provides limited insight into the economics of the agreement. It does not publicly confirm:
- A specific royalty rate.
- An authorized-generic commitment.
- A payment arrangement.
- A supply agreement.
- A launch date earlier than patent expiration.
- A no-challenge provision.
- A license covering later-issued or later-listed patents.
For antitrust and market-entry analysis, the settlement must be evaluated separately from the docket dismissal. A dismissal alone does not establish whether the agreement was an early-entry settlement, a license, or a broader commercial arrangement.
What generic launch risks existed for Mylan?
Mylan faced four primary risks.
Regulatory risk
FDA approval could have been delayed by the Hatch-Waxman litigation stay, patent certifications, or deficiencies in the ANDA. The risk diminished after patent expiration and FDA approval of generic pregabalin products.
Infringement risk
A product that carried the same indication set as Lyrica could expose Mylan to method-of-use infringement claims. A carved-out label could reduce that risk but would also restrict the approved commercial indications.
Launch-timing risk
An at-risk launch before final resolution could have exposed Mylan to damages and potential injunctive relief. The settlement likely provided greater certainty than an unlicensed launch.
Commercial erosion risk
Pregabalin was a large branded market. Generic entry was expected to produce rapid price erosion, particularly for capsule strengths with multiple approved suppliers. Mylan’s value depended on launch timing, supply capacity, label scope, and the number of competing generic manufacturers entering at the same time.
Did biosimilar law apply to this case?
No. Lyrica is a small-molecule drug, and Mylan’s application was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The case did not involve a biologics license application, a biosimilar application under section 351(k) of the Public Health Service Act, or the Biologics Price Competition and Innovation Act.
The relevant competitive threats were generic pregabalin products, not biosimilars.
How did Pfizer v. Mylan compare with other Lyrica cases?
The Mylan action was one of several coordinated commercial disputes over pregabalin. The cases shared a common product and patent estate but could differ in:
- ANDA dosage forms.
- Proposed indication sets.
- Section viii carve-outs.
- Paragraph IV positions.
- Settlement dates.
- Launch licenses.
- Defendants’ manufacturing processes.
- Alleged induced-infringement theories.
A decision in one Lyrica case did not automatically resolve every issue in the Mylan case. Each ANDA had to be evaluated based on its own formulation, label, certification, and proposed manufacturing process.
Key Takeaways
- Pfizer v. Mylan, No. 1:15-cv-00960-SLR-SR, concerned generic pregabalin, the active ingredient in Lyrica.
- Pfizer relied on the Lyrica patent estate, including compound and method-of-use patents.
- Mylan’s ANDA triggered Paragraph IV Hatch-Waxman litigation.
- The case ended through settlement and dismissal rather than a publicly reported merits judgment.
- Settlement terms and the specific commercial launch provisions were confidential.
- Lyrica’s broad compound protection expired in late 2018, with pediatric exclusivity extending the practical barrier into 2019.
- Generic pregabalin competition began in 2019 after FDA approvals and the end of the principal exclusivity period.
- Method-of-use patents remained relevant after compound-patent expiration, particularly for labeling and induced-infringement analysis.
- The case involved generics, not biosimilars.
- The public record does not establish a final judicial ruling that the asserted patents were valid, invalid, infringed, or not infringed.
FAQs About Pfizer v. Mylan Laboratories Ltd.
What product did Mylan seek to market in the case?
Mylan sought approval for generic pregabalin, the active ingredient in Pfizer’s Lyrica products.
Was Pfizer v. Mylan a Paragraph IV case?
Yes. The litigation arose from Mylan’s ANDA and Paragraph IV patent certification concerning Pfizer’s Lyrica-related patents.
Did Pfizer win the case at trial?
No public merits judgment resolved the dispute. The case was settled and dismissed.
Did the case block generic pregabalin permanently?
No. The principal Lyrica compound patent expired in late 2018, pediatric exclusivity ended in 2019, and generic pregabalin products entered the U.S. market during 2019.
Did the litigation concern Lyrica capsules or a biologic product?
It concerned a small-molecule pregabalin product, not a biologic. The relevant FDA pathway was an ANDA, not a biosimilar application.
References
- U.S. Food and Drug Administration. (2023). Lyrica (pregabalin) prescribing information. FDA.
- Pfizer Inc. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1352 (Fed. Cir. 2017).
- U.S. Food and Drug Administration. (2019). FDA approves first generics of Lyrica. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Lyrica patent and exclusivity information. FDA.
- Pfizer Inc. v. Mylan Laboratories Ltd., No. 1:15-cv-00960-SLR-SR (D. Del.).
